Research programme: hepatitis E and human papilloma virus vaccines - Chongqing Zhifei/Hong Kong University

Drug Profile

Research programme: hepatitis E and human papilloma virus vaccines - Chongqing Zhifei/Hong Kong University

Alternative Names: HEV vaccine - Chongquing Zhifei/Hong Kong University; HPV vaccine - Chongqing Zhifei/Hong Kong University

Latest Information Update: 17 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chongqing Zhifei Biological Products; Hong Kong University of Science and Technology
  • Developer Chongqing Zhifei Biological Products
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis E; Human papillomavirus infections

Most Recent Events

  • 17 Jul 2016 Preclinical development in Hepatitis E virus prevention is ongoing in China
  • 15 Jul 2016 Preclinical trials in Human papillomavirus infections (Prevention) in China (Parenteral)
  • 02 Apr 2013 Preclinical trials in Hepatitis E in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top